Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017, Article ID 2842935, 3 pages
https://doi.org/10.1155/2017/2842935
Case Report

Development of New Deep Venous Thrombosis While on Apixaban

1Department of Internal Medicine, Easton Hospital, Easton, PA, USA
2Drexel University College of Medicine, Electrophysiology Department, Easton Hospital, Easton, PA, USA

Correspondence should be addressed to Munish Sharma; moc.liamg@demtnihsinum

Received 24 April 2017; Revised 17 May 2017; Accepted 29 May 2017; Published 20 June 2017

Academic Editor: Konstantinos P. Letsas

Copyright © 2017 Munish Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin with atrial fibrillation,” The New England Journal of Medicine, vol. 361, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar
  2. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” New England Journal of Medicine, vol. 365, pp. 883–891, 2011. View at Google Scholar
  3. G. Agnelli, H. R. Buller, A. Cohen et al., “Apixaban for extended treatment of venous thromboembolism,” The New England Journal of Medicine, vol. 368, no. 8, pp. 699–708, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. A. Reilly, T. Lehr, and S. Haertter, “The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients,” Journal of the American College of Cardiology, vol. 63, no. 4, pp. 321–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C. T. Ruff, R. P. Giugliano, E. Braunwald et al., “Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial,” The Lancet, vol. 385, no. 9984, pp. 2288–2295, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Z. Goldhaber and H. Bounameaux, “Pulmonary embolism and deep vein thrombosis,” The Lancet, vol. 379, no. 9828, pp. 1835–1846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Schulman, A. K. Kakkar, and S. Z. Goldhaber, “Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis,” Circulation, vol. 129, RE-COVER II Trial Investigators, no. 7, pp. 764–772, 2014. View at Publisher · View at Google Scholar
  8. M. Molteni and C. Cimminiello, “Warfarin and atrial fibrillation: from ideal to real the warfarin affaire,” Thrombosis Journal, vol. 12, no. 5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Agnelli, H. R. Buller, A. Cohen et al., “Oral apixaban for the treatment of acute venous thromboembolism,” The New England Journal of Medicine, vol. 369, AMPLIFY Investigators, pp. 799–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. G. Goodman, D. M. Wojdyla, J. P. Piccini et al., “Factors associated with major bleeding events: insights from the ROCKET AF trial,” Journal of the American College of Cardiology, vol. 63, pp. 891–900, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Powell, “Are New Oral Anticoagulant Dosing Recommendations Optimal for All Patients?” JAMA, vol. 313, no. 10, p. 1013, 2015. View at Publisher · View at Google Scholar
  12. A. Cuker, D. M. Siegal, M. A. Crowther, and D. A. Garcia, “Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants,” Journal of the American College of Cardiology, vol. 64, no. 11, pp. 1128–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Gouin-Thibault, C. Flaujac, X. Delavenne et al., “Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays,” Thrombosis and Haemostasis, vol. 111, no. 2, pp. 240–248, 2014. View at Publisher · View at Google Scholar · View at Scopus